Dose rate in external beam radiotherapy for prostate cancer: An overlooked confounding variable?

Urology

Volumn 62, Issue 2, 2003, Pages 204-206

  Welsh, James S ^a   Howard, Steven P ^a   Fowler, Jack F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER RADIOTHERAPY; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE FRACTIONATION; STANDARDIZATION; TREATMENT OUTCOME;

EID: 0041622719     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00375-3     Document Type: Editorial

References (14)

1. Shu H.K., Lee T.T., Vigneauly E., et al. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology. 57:2001;102-107.
2. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer early toxicity and biochemical outcome in 772 patients . Int J Radiat Oncol Biol Phys. 53:2002;1111-1116.
3. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 5:1999;152-158.
4. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
5. Zaider M., Zelefsky M.J., Hanin L.G., et al. A survival model for fractionated radiotherapy with an application to prostate cancer. Phys Med Biol. 46:2001;2745-2758.
6. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031.
7. Haustermans K.M., Hofland I., Van Poppel H., et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;1067-1070.
8. Schmid H.P. Tumor markers in patients on deferred treatment prostate specific antigen doubling times . Cancer Surv. 23:1995;157-167.
9. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;904-912.
10. Benedict S.H., Lin P.S., Zwicker R.D., et al. The biological effectiveness of intermittent irradiation as a function of overall treatment time development of correction factors for LINAC-based stereotactic radiotherapy . Int J Radiat Oncol Biol Phys. 37:1997;765-769.
11. Zackrisson B, Karlsson M, and Lofroth P: Biological effect of prolonged fraction delivery time in intensity modulated radiotherapy (IMRT) - in vitro simulation and model evaluation. Radiother Oncol 56(suppl 1): S195-S196, 2001.
12. Morgan W.F., Naqvi C., Yu C., et al. Does the time required to deliver IMRT reduce its biological effectiveness (abstract)? Int J Radiat Oncol Biol Phys. 54:(suppl):2002;222.
13. Welsh J., Fowler J., Burkhammer M., et al. Radiation dose-rate considerations with intensity modulated radiotherapy. (abstract) Radiother Oncol. 64:(suppl):2002;S312.
14. McNair H. Clinical IMRT impact on a radiotherapy department . (abstract) Radiother Oncol. 64:(suppl):2002;S79.